ruthenium has been researched along with Alzheimer Disease in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.56) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (16.67) | 24.3611 |
| 2020's | 14 (77.78) | 2.80 |
| Authors | Studies |
|---|---|
| Cen, J; Chen, X; Gong, Y; Guo, X; Huang, Y; Jia, Z; Li, J; Liu, J; Liu, Y; Yuan, X | 1 |
| Apuzzo, CF; Bothwell, PJ; Ferrence, GM; Hamaker, CG; Huffman, SE; Jones, MA; Oliver, EB; Platt, DC; Strandquist, ET; Webb, MI; Weitzel, CS; Will, MF; Yawson, GK | 1 |
| Angeletti, M; Bonfili, L; Cecarini, V; Cuccioloni, M; Eleuteri, AM; Pagliaricci, N; Petetta, L; Pettinari, R; Tombesi, A | 1 |
| Bhattacharya, U; Chen, HJ; Kong, KV; Lin, D; Liu, YH; Tai, HC; Tsai, SW; Wu, CY; Wu, YC | 1 |
| Cao, J; Li, Z; Liu, C; Song, Z; Sun, Y; Wei, D; Yan, J; Yu, H; Zhang, H | 1 |
| Bothwell, PJ; Ehlbeck, JT; Garcia, JA; Grimard, DM; Hacker, RM; Jones, MA; Wall, BJ; Webb, MI | 1 |
| Gong, Y; Huang, A; Liu, J; Liu, Y; Wei, JA; Yuan, G; Zhang, L; Zhou, H; Zhu, X | 1 |
| Hu, X; Liu, W; Shi, S; Tu, Y; Yao, T; Zhou, L | 1 |
| Bothwell, PJ; Fisher, SS; Hamaker, CG; Huffman, SE; Jones, MA; Platt, DC; Webb, MI; Yawson, GK | 1 |
| Bothwell, PJ; Ferrence, GM; Fisher, SS; Hamaker, CG; Huffman, SE; Jones, MA; Platt, DC; Webb, MI; Yawson, GK | 1 |
| Cali, MP; Carlos, RM; Pereira, LMB; Rodrigues, EG; Sellani, TA; Teodoro, MD | 1 |
| Apuzzo, CF; Bothwell, PJ; Ferrence, GM; Jones, MA; Platt, DC; Wall, BJ; Webb, MI; Will, MF; Yawson, GK | 1 |
| Almeida, MP; Carlos, RM; de Jesus, HCR; Kock, FVC; Venâncio, T | 1 |
| Peng, YB; Tan, CP; Tao, C; Zhao, P | 1 |
| Bhat, SS; Jani, V; Joshi, B; Joshi, RR; Kulkarni, PP; Kumbhar, AS; Ramteke, SN; Sonawane, UB; Vyas, NA | 1 |
| Arcisio-Miranda, M; Cali, MP; Carlos, RM; Carlos-Lima, E; Ito, AS; Pazin, WM; Salles Trevisan, MT; Silva, DE; Venâncio, T | 1 |
| Anzini, P; Cini, R; Gabbiani, C; Gaggelli, E; Gaggelli, N; Kozlowski, H; Messori, L; Michelucci, E; Tamasi, G; Valensin, D; Valensin, G | 1 |
| Lara, S; Nochlin, D; Snow, AD; Wight, TN | 1 |
18 other study(ies) available for ruthenium and Alzheimer Disease
| Article | Year |
|---|---|
A diselenide bond-containing ROS-responsive ruthenium nanoplatform delivers nerve growth factor for Alzheimer's disease management by repairing and promoting neuron regeneration.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Biocompatible Materials; Blood-Brain Barrier; Brain; Cell Line, Tumor; Drug Carriers; Hemolysis; Humans; Infrared Rays; Nanostructures; Nerve Growth Factor; Nerve Regeneration; Neuronal Outgrowth; Reactive Oxygen Species; Ruthenium; Selenium | 2021 |
A Dual-Pronged Approach: A Ruthenium(III) Complex That Modulates Amyloid-β Aggregation and Disrupts Its Formed Aggregates.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Survival; Coordination Complexes; Dose-Response Relationship, Drug; Humans; Models, Molecular; Molecular Conformation; Neuroprotective Agents; Oxazoles; Protein Aggregates; Rats; Ruthenium; Structure-Activity Relationship; Tumor Cells, Cultured | 2022 |
Enhancing the Amyloid-β Anti-Aggregation Properties of Curcumin via Arene-Ruthenium(II) Derivatization.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Curcumin; Humans; Ruthenium | 2022 |
Highly Efficient Singlet Oxygen Generation by BODIPY-Ruthenium(II) Complexes for Promoting Neurite Outgrowth and Suppressing Tau Protein Aggregation.
Topics: Alzheimer Disease; Boron; Humans; Neuronal Outgrowth; Photosensitizing Agents; Protein Aggregates; Ruthenium; Singlet Oxygen; tau Proteins | 2023 |
Visualization of the elevated levels of hypochlorous acid in Alzheimer's disease with a ruthenium(II) complex-based luminescence probe.
Topics: Alzheimer Disease; Fluorescent Dyes; Humans; Hypochlorous Acid; Luminescence; Ruthenium | 2023 |
Finding the best location: Improving the anti-amyloid ability of ruthenium(III) complexes with pyridine ligands.
Topics: Alzheimer Disease; Amines; Amyloid beta-Peptides; Humans; Ligands; Magnetic Resonance Spectroscopy; Pyridines; Ruthenium | 2024 |
Intelligently thermoresponsive flower-like hollow nano-ruthenium system for sustained release of nerve growth factor to inhibit hyperphosphorylation of tau and neuronal damage for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Delayed-Action Preparations; Mice; Nerve Growth Factor; Phosphorylation; Ruthenium; tau Proteins | 2020 |
Orientation-Inspired Perspective on Molecular Inhibitor of Tau Aggregation by Curcumin Conjugated with Ruthenium(II) Complex Scaffold.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Curcumin; Humans; Ruthenium; tau Proteins | 2020 |
Ruthenium(iii) complexes containing thiazole-based ligands that modulate amyloid-β aggregation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Line, Tumor; Cell Survival; Coordination Complexes; Crystallography, X-Ray; Humans; Ligands; Microscopy, Electron, Transmission; Peptide Fragments; Protein Aggregates; Rats; Ruthenium; Structure-Activity Relationship; Thiazoles | 2020 |
Ruthenium(III) complexes with imidazole ligands that modulate the aggregation of the amyloid-β peptide via hydrophobic interactions.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Coordination Complexes; Humans; Imidazoles; Protein Aggregates; Ruthenium | 2021 |
Comparison of Aβ (1-40, 1-28, 11-22, and 29-40) aggregation processes and inhibition of toxic species generated in early stages of aggregation by a water-soluble ruthenium complex.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Survival; Coordination Complexes; Microscopy, Electron, Transmission; PC12 Cells; Peptide Fragments; Protein Aggregation, Pathological; Rats; Ruthenium; Solubility; Water | 2021 |
Importance of Hydrogen Bonding: Structure-Activity Relationships of Ruthenium(III) Complexes with Pyridine-Based Ligands for Alzheimer's Disease Therapy.
Topics: Alzheimer Disease; Animals; Cell Line, Tumor; Cell Survival; Coordination Complexes; Dose-Response Relationship, Drug; Humans; Hydrogen Bonding; Ligands; Molecular Structure; Neuroprotective Agents; Pyridines; Rats; Ruthenium; Structure-Activity Relationship | 2021 |
Probing the acetylcholinesterase inhibitory activity of a novel Ru(II) polypyridyl complex and the supramolecular interaction by (STD)-NMR.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Coordination Complexes; Humans; Magnetic Resonance Spectroscopy; Molecular Structure; Pyridines; Ruthenium | 2021 |
Inhibition of Aβ peptide aggregation by ruthenium(II) polypyridyl complexes through copper chelation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Benzimidazoles; Cell Line, Tumor; Cell Survival; Chelating Agents; Coordination Complexes; Copper; Humans; Mitochondria; Neurons; Oxyquinoline; Protein Aggregates; Protein Aggregation, Pathological; Reactive Oxygen Species; Ruthenium | 2021 |
Ruthenium(II) polypyridyl complex as inhibitor of acetylcholinesterase and Aβ aggregation.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Cell Line, Tumor; Cholinesterase Inhibitors; Coordination Complexes; Humans; Organometallic Compounds; Phenanthrolines; Pyridines; Ruthenium | 2014 |
Luminescent Ru(II) Phenanthroline Complexes as a Probe for Real-Time Imaging of Aβ Self-Aggregation and Therapeutic Applications in Alzheimer's Disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Cell Line; Cholinesterase Inhibitors; Electrophorus; Humans; Luminescent Agents; Mice; Optical Imaging; Phenanthrolines; Protein Aggregates; Ruthenium | 2016 |
fac-{Ru(CO)(3)}(2+) selectively targets the histidine residues of the beta-amyloid peptide 1-28. Implications for new Alzheimer's disease treatments based on ruthenium complexes.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Circular Dichroism; Drug Design; Histidine; Humans; Magnetic Resonance Spectroscopy; Molecular Conformation; Organometallic Compounds; Peptide Fragments; Ruthenium; Spectrometry, Mass, Electrospray Ionization | 2010 |
Cationic dyes reveal proteoglycans structurally integrated within the characteristic lesions of Alzheimer's disease.
Topics: Alzheimer Disease; Humans; Indoles; Microscopy, Electron; Organometallic Compounds; Proteoglycans; Ruthenium; Ruthenium Red; Staining and Labeling | 1989 |